Escalating and De-escalating Treatments in HRHER2 Early-stage Breast Cancer

Overview

Journal Transl Breast Cancer Res

Publisher AME Publishing Company

Date 2024 May 16

PMID 38751532

Authors

Rui Ge

Affiliations

Soon will be listed here.

Citing Articles

Five-year survival in luminal breast cancer patients: relation with intratumoral activity of proteasomes.

Sereda E, Kolegova E, Kakurina G, Korshunov D, Sidenko E, Doroshenko A Transl Breast Cancer Res. 2024; 3:23.

PMID: 38751528 PMC: 11093047. DOI: 10.21037/tbcr-22-22.

References

Mayer E, Dueck A, Martin M, Rubovszky G, Burstein H, Bellet-Ezquerra M . Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021; 22(2):212-222. DOI: 10.1016/S1470-2045(20)30642-2. View

Zhang L, Zhou M, Liu Y, Du F, Tang J, Wang N . Is it beneficial for patients with pT1-2N1M0 breast cancer to receive postmastectomy radiotherapy? An analysis based on RecurIndex assay. Int J Cancer. 2021; 149(10):1801-1808. DOI: 10.1002/ijc.33730. View

Cardoso F, Vant Veer L, Bogaerts J, Slaets L, Viale G, Delaloge S . 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375(8):717-29. DOI: 10.1056/NEJMoa1602253. View

Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2018; 379(2):111-121. PMC: 6172658. DOI: 10.1056/NEJMoa1804710. View

Loibl S, Marme F, Martin M, Untch M, Bonnefoi H, Kim S . Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021; 39(14):1518-1530. DOI: 10.1200/JCO.20.03639. View

Johnston S, Harbeck N, Hegg R, Toi M, Martin M, Shao Z . Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020; 38(34):3987-3998. PMC: 7768339. DOI: 10.1200/JCO.20.02514. View

Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P . Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer. N Engl J Med. 2021; 384(25):2394-2405. PMC: 9126186. DOI: 10.1056/NEJMoa2105215. View

Zhang S, Liu B, Zhou M, Wang J, Liu J, Wang L . The beneficial role of Asian-based RecurIndex test in the prognostic prediction in Chinese male breast cancer patients. Sci Rep. 2021; 11(1):7657. PMC: 8026596. DOI: 10.1038/s41598-021-87267-y. View

Piccart M, J van t Veer L, Poncet C, Lopes Cardozo J, Delaloge S, Pierga J . 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021; 22(4):476-488. DOI: 10.1016/S1470-2045(21)00007-3. View

10.

Kalinsky K, Barlow W, Gralow J, Meric-Bernstam F, Albain K, Hayes D . 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. N Engl J Med. 2021; 385(25):2336-2347. PMC: 9096864. DOI: 10.1056/NEJMoa2108873. View